Axonics Modulation Tech
#3300
Rank
$3.56B
Marketcap
United States
Country
Mr. Raymond W. Cohen (CEO & Director)
Mr. Danny L. Dearen (Pres & CFO)
Mr. Rinda K. Sama (Chief Operating Officer)
Summary
History
Axonics Modulation Technologies Inc. was founded in 2013 to develop a unique implantable device for sacral neuromodulation therapies — using radio frequency delivered through an implantable pulse generator. In 2019, Axonics was the first to receive premarket approval (PMA) from the FDA for a rechargeable implantable neuromodulation device. The approval allowed Axonics to provide its bladder and bowel control offering on a broader scale in the U.S. and worldwide.
Mission
Vision
Key Team
Dr. John Woock Ph.D. (Exec. VP, Chief Marketing & Strategy Officer)
Mr. Alfred J. Ford Jr. (Chief Commercial Officer)
Mr. Guangqiang Jiang Ph.D. (Chief Technology Officer)
Mr. Neil Bhalodkar (VP of Investor Relations)
Mr. Michael V. Williamson Esq., J.D. (Sr. VP, Gen. & IP Counsel)
Mr. Aaron Pettit (Gen. Counsel & Chief Compliance Officer)
Dr. Karen L. Noblett M.A.S., M.D. (Chief Medical Officer)
Recognition and Awards
References
https://in.investing.com/equities/axonics-modulation-technologies
https://finance.yahoo.com/quote/AXNX/profile?p=AXNX
https://www.comparably.com/companies/axonics-modulation-technologies
https://www.crunchbase.com/organization/axonics-modulation-technologies
https://sec.report/CIK/0001603756
Mr. Raymond W. Cohen (CEO & Director)
Mr. Danny L. Dearen (Pres & CFO)
Mr. Rinda K. Sama (Chief Operating Officer)